However, lebrikizumab did not consistently show statistically significant reductions in asthma exacerbations in biomarker‐high adult patients (periostin ≥50 ng/ml, blood eosinophil count ≥300 cells/μl, or both); the primary endpoint was met in LAVOLTA I but not in LAVOLTA II. The gene discussed is POSTN; the disease is asthma.